Objective Impaired glycaemic control, characteristic of acromegaly, can be exacerbated by treatment with somatostatin analogues (SSAs), particularly those with multireceptor activity. We present data from the PRIMARYS study on the impact of the SSA lanreotide, associated with tumour volume and hormonal improvements, on glucose and other metabolic parameters in acromegaly. Design PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks. A priori and post hoc metabolic profile data are reported for the overall population, patients with/without diabetes and patients achieving/not achieving hormonal control. Patients Treatment-na€ ıve adults with pituitary macroadenoma, mean growth hormone >1 lg/l and elevated insulin-like growth factor-1 levels (n = 90). Measurements Glycaemic parameters [glycated haemoglobin (HbA 1c ) and fasting plasma glucose (FPG) levels] assessed at baseline and weeks 12, 24 and 48. Lipid-profile data (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) collected at baseline and study end. Results In patients with diabetes (n = 24), HbA 1c showed a clinically relevant decrease during treatment [mean change from baseline to week 48, À1Á44% (95% CI: À2Á52, À0Á36)]. In the overall population, in patients without diabetes, or in patients with/without hormonal control, HbA 1c did not significantly change by week 48. Mean FPG levels showed no significant change by week 48 in all populations. Individually, increases and decreases in glycaemic parameters affected some patients in all populations. Glycaemic status as a composite measure of HbA 1c and FPG (classification as normal, mild or diabetic) was stable from baseline to study end in most patients (overall, 70%; patients with diabetes, 50%; patients without diabetes, 76%), but worsened by week 48 in nine (15%) patients [seven (50%) with diabetes at baseline] and improved in nine (15%) patients (none with diabetes). Changes in lipid profiles were not considered clinically meaningful. Conclusions Glucose and lipid levels were not detrimentally affected in most patients, while only a relatively small proportion showed deterioration in glucose control.
Introduction
Medical management of acromegaly aims to relieve clinical symptoms, reduce growth hormone (GH) levels, normalize insulin-like growth factor 1 (IGF-1) levels, control pituitary tumour mass and reduce comorbidities. 1, 2 Metabolic abnormalities, including impaired glucose tolerance and insulin resistance, are increased in acromegaly, contributing to greater risks of diabetes. 2, 3 Furthermore, dyslipidaemia and hypertension are more frequent than in the general population and are associated with an increased incidence of cardiovascular morbidity and mortality. [4] [5] [6] Medical management therefore should correct hormone levels and reduce tumour size without contributing to metabolic impairment. Long-acting formulations of somatostatin analogues (SSAs), such as lanreotide autogel (lanreotide depot in the USA), are recommended first-line treatments for acromegaly after surgery or when surgery is inappropriate. 1, 2 Whereas SSA treatment counteracts disease-related lipid abnormalities and reduces cardiovascular risk, it has sometimes been implicated in the exacerbation of impaired glucose tolerance and the development of type 2 diabetes in acromegaly. 1, 2, 7 Accordingly, monitoring blood glucose and glycated haemoglobin (HbA 1c ) is recommended in acromegaly management. 1 The reported influence of lanreotide autogel and octreotide LAR on glucose metabolism has been inconsistent. Any effect is generally considered to be of marginal clinical relevance, but might be most frequent in patients not achieving hormonal control. 1, 2, 7, 8 A study in patients requiring increased dose and/or frequency of octreotide LAR owing to persistently uncontrolled acromegaly found, for example, that unremittent biochemical activity of the disease was associated with worsened glucose-metabolic status, whereas the SSA dose increase and pre-existing metabolic status were not significantly associated with glycaemic control. 8 However, these studies used small, heterogeneous populations, and varied SSA dose and treatment contexts. 9 By contrast, the risk of disrupted glucose metabolism with somatostatin multireceptor ligands, such as pasireotide LAR, is well described. Recently approved in the USA for patients with acromegaly with inadequate response to surgery and/or for whom surgery is not an option, 10 and in Europe for patients in the same situation with regard to surgery who are inadequately controlled on treatment with an established SSA, 11 pasireotide LAR has greater deleterious effects on glucose metabolism than other approved SSAs. 2, 12, 13 With the advent of somatostatin multireceptor ligands, therefore, and given potential concerns over glycaemic disruption with SSAs still not entirely dispelled, further data are needed on the metabolic effects of established SSAs, such as lanreotide autogel.
In the PRIMARYS study, patients with acromegaly who had not undergone prior surgery or radiotherapy for a GH-secreting macroadenoma received primary treatment with lanreotide autogel at the maximum 120 mg dose. Of the 90 patients included, 63% had a tumour volume reduction of ≥20% by study end (week 48)/last postbaseline value available (LVA).
14 This was concomitant with improved hormonal control: at week 48, 77Á8% of patients had GH levels ≤2Á5 lg/l, 50Á0% had normalized IGF-1 levels and 43Á5% had hormonal control (GH ≤ 2Á5 lg/l and within age-and sex-matched normal range IGF-1). 14 The purpose of analyses was to use the PRIMARYS data set to investigate the effect of lanreotide autogel 120 mg on glycaemic control and lipid metabolism. The inherent advantages of this data set were principally the large size and homogeneous nature of the study population of treatment-na€ ıve patients and consistency of dosing (at highest approved dose from the outset). Here, we present both a priori and post hoc analyses for the overall PRI-MARYS population, and according to baseline diabetic status, and whether hormonal control was achieved at LVA. We additionally examine glycaemic profiles in individual patients and investigate correlations between IGF-1 or GH level changes and glycaemic and lipid profile changes during the study.
Methods

Trial design
The 48-week open-label single-arm phase 3b PRIMARYS study was conducted at 27 specialist endocrinology centres in Belgium, the Czech Republic, Finland, France, Germany, Italy, the Netherlands, Turkey and the UK between 20 May 2008 and 13 February 2012 (NCT00690898; EudraCT: 2007-000155-34). The trial was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and all local regulatory requirements. Ethical statements and full study methods have been published previously. 14 
Patients and interventions
PRIMARYS enrolled treatment-na€ ıve adults with acromegaly and a pituitary macroadenoma, mean GH >1 lg/l and elevated IGF-1 levels. Patients were excluded if they had visual defects and elevated prolactin (>100 lg/l), had previously received a SSA or were likely to require radiotherapy or surgery.
14 Patients received lanreotide autogel 120 mg (highest recommended dose, without titration) injected subcutaneously every 4 weeks for 48 weeks (a total of 12 injections).
Patients were withdrawn in the event of evidence of visual field abnormalities, insufficient IGF-1 response (IGF-1 levels reduced by <10% vs baseline at week 24 or investigator-judged inadequate response) and postbaseline secretion of prolactin >100 lg/l (for patients with baseline levels of 20-100 lg/l) or if there were any safety concerns. 14 The safety population comprised all patients who received at least one lanreotide dose; the intention-to-treat (ITT) population included patients from the safety population with at least one efficacy assessment for the primary end-point. Diabetic status was determined for the safety population at baseline; patients with diabetes fulfilled one or more of the following criteria: a medical history of diabetes; HbA 1c level ≥6Á5% (47Á5 mmol/ mol); fasting plasma glucose (FPG) level ≥7 mmol/l (≥126 mg/ dl); previous/current use of antidiabetes medications [oral antidiabetic drug (OAD) or insulin prescribed for diabetes].
Metabolic assessments and analyses
Hormonal levels (GH, IGF-1) and glycaemic parameters (FPG, HbA 1c ) were centrally assessed at day 1 (baseline), and at weeks 12, 24 and 48 (study end), or early withdrawal visit. Fasting lipid levels (triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol] were centrally assessed at baseline and week 48, or early withdrawal visit.
Insulin-like growth factor 1 levels were assessed at each visit by radioimmunoassay from a single sample. Mean GH level for each visit was determined from five consecutive samples taken at 10-15 intervals by one-step immunoenzymatic assay. Mean HbA 1c , FPG and fasting lipid levels were calculated for patients with/without diabetes (safety population) and for patients with/ without hormonal control (GH ≤ 2Á5 lg/l and IGF-1 within age-and sex-matched normal ranges) at LVA (ITT population). These summaries included a priori analyses in the overall population of HbA 1c , FPG and total cholesterol, as well as post hoc analyses according to diabetic status and hormonal control status at LVA.
Evaluating changes in mean levels may disguise clinically meaningful effects in individual patients. Therefore, glycaemic profile data were analysed for individual patients according to thresholds for diabetes and prediabetes determined by the American Diabetes Association (ADA), 15 Changes in patient characteristics relevant to cardiovascular risk were evaluated, comprising a priori analyses of systolic blood pressure (SBP), diastolic blood pressure (DBP) and body mass index (BMI) in the overall population, and post hoc analyses of these end-points according to baseline diabetic status (safety population) and hormonal control at LVA (ITT population).
To further examine relationships between hormonal control and metabolic parameters, correlations between IGF-1 or GH changes and glycaemic or fasting lipid changes were examined (ITT population).
Exploratory analyses were undertaken to identify potential baseline predictive factors for changes in metabolic parameters, as described and reported in the Supplementary Information. These analyses are not discussed further in the main manuscript as the subgroups of patients experiencing clinically relevant changes were small, and consequently, no associations of clinical relevance were identified.
Statistical analyses
Post hoc analyses of metabolic parameters used descriptive summary statistics [mean, standard deviation (SD) and 95% confidence intervals (95% CIs)] on raw and change-from-baseline data; the significance of changes was determined on the basis of 95% CIs. Repeated measures analyses were performed using a mixed model adjusting for diabetic status at baseline, time point (baseline, week 12, week 24 and week 48), level of LDL cholesterol at baseline and the interactions between time and diabetic status at baseline to assess the evolution of HbA 1c and FPG during the course of the study. Shift tables were compiled to show the proportions of patients within categories of glycaemic status (based on a composite of HbA 1c and FPG ADA categories) during the study. Pearson's correlations between changes from baseline in IGF-1 or GH and glycaemic and fasting lipid changes were assessed, and P values were calculated.
Results
Baseline characteristics and diabetic status
The safety population comprised 90 patients, 14 with mean AE SD age of 49Á5 AE 12Á4 years, GH levels of 15Á0 AE 18Á8 lg/l and IGF-1 levels of 810 AE 300 lg/l. Baseline characteristics are presented according to diabetic status in Table 1a (safety population) and hormonal control at LVA in Table 1b (ITT population) . One patient (without diabetes) was excluded from the ITT population (n = 89; missing baseline tumour volume assessment); one patient (with diabetes) was excluded from the analyses by hormonal control at LVA (lack of a postbaseline IGF-1 value).
Twenty-four patients (27%) had diabetes at baseline, 19 of whom (79%) had a medical history of diabetes. Baseline glycaemic control varied among these patients, but most had HbA 1c and/or FPG levels above the ADA criteria for diabetes (Table 1a) . 15 Many patients without diabetes had blood glucose elevated to prediabetes/impaired levels (Table 1a) . Fifteen patients with diabetes (62Á5%) were using antidiabetes medications at baseline (six used one OAD; two used two OADs; one used three OADs; four were using combined insulin plus ≥1 OAD, and two were using insulin alone). Two patients with diabetes started initial antidiabetes medication during the study (after first intake of study drug), and two changed their medication regimen (Table S1 ).
Glycaemic control during the study according to diabetic status
Mean HbA 1c and FPG levels were stable during the study, with no evidence of deterioration for the population as a whole or for patients with/without diabetes ( Fig. 1) .
Mean HbA 1c levels overall and in patients without diabetes were within 5Á7-6Á4% at all time points ( Fig. 1a and b) . Overall, mean HbA 1c was 6Á3% at baseline (n = 87) and 6Á1% at week 48 (n = 62). Mean changes from baseline to weeks 12, 24 or 48 were all nonsignificant in the overall population. In patients without diabetes, small increases from baseline to weeks 12 and 24 in HbA 1c were statistically significant, but not considered clinically relevant [week 12: 0Á12% (95% CI: 0Á05; 0Á19), n = 61; week 24: 0Á13% (0Á03; 0Á23), n = 55], whereas the change to week 48 was not statistically significant (n = 47). Patients with diabetes had mean baseline HbA 1c of 8Á0% (n = 22) and week 48 value of 6Á8% (n = 15). Data for change from baseline showed changes to weeks 12 (n = 19) and 24 (n = 16) that were not statistically significant and, by week 48, a statistically significant and clinically relevant decrease in HbA 1c of À1Á44% (95% CI: À2Á52, À0Á36; n = 14).
Mean FPG levels in the overall population were 6Á5 mmol/l at baseline (n = 88) and 6Á2 mmol/l at week 48 (n = 64; Fig. 1c  and d ). Similar to HbA 1c , mean levels in the overall population and in patients without diabetes were in the range of impaired FPG (5Á6-6Á9 mmol/l) at all time points. Changes in mean FPG levels in all populations to each time point were not significant, except for statistically significant increases to weeks 12 and 24 in patients without diabetes, not considered clinically relevant [week 12: 0Á24 mmol/l (95% CI: 0Á07; 0Á40), n = 53; week 24: 0Á26 mmol/l (0Á08; 0Á43), n = 54].
For both HbA 1c and FPG, a significant interaction between the visit (time point) and diabetic status was identified. For HbA 1c , the estimates of the adjusted (least-squares mean) differences (with diabetes vs without diabetes) and their associated 95% CIs at baseline, week 12, week 24 and week 48 were 1Á79 (1Á4; 2Á1), 1Á5 (1Á2; 1Á8), 1Á2 (1Á0; 1Á5) and 0Á6 (0Á1; 1Á1). Similarly, the FPG estimates were 3Á0 (2Á3, 3Á7), 2Á5 (2Á0, 3Á0), 2Á1 (1Á6, 2Á6) and 1Á2 (0Á2, 2Á1).
For individual patients, deterioration of glycaemic control by study end (based on ADA thresholds 15 ) to levels considered diabetic occurred infrequently (Fig. 2 , Table 2 ). Twelve (20%) patients showed HbA 1c decreases, with nine (15%) crossing below the diabetes threshold. Nine (15%) patients showed HbA 1c increases, but none entered the diabetes category (Fig. 2a) . For FPG, seven (11%) patients showed decreases, with three (5%) improving from diabetic to impaired FPG. Seventeen (27%) patients showed FPG increases [five (8%) to diabetes level; Fig. 2b] . A composite definition of glycaemic status, incorporating both HbA 1c and FPG thresholds (Table 2) , revealed nine (15%) patients in the overall safety population improved glycaemic status at week 48, while 42 (70%) patients remained stable and only nine (15%) patients deteriorated (Table 2a) . Of patients with diabetes at baseline, seven (50%) remained stable, while the other seven (50%) deteriorated at week 48 (Table 2b) .
Of the patients without diabetes at baseline, an improvement was seen in nine (20%) patients, while 35 (76%) remained stable and two (4%) deteriorated (Table 2c) . Changes in nonpharmacological management were not recorded, but four patients with diabetes started or changed antidiabetes medication during the study (after first intake of study drug; Table S1 ). Nevertheless, only two were included in calculations of mean changes (having week 48 data available). Glucose profiles for these patients are distinguished from others (Fig. 2, Figure S1 ). One improved by an ADA category in both HbA 1c and FPG, whereas the other improved only in HbA 1c . (62Á5%) patients with diabetes were using antidiabetes medication (one OAD, n = 6; two OADs, n = 2; three OADs, n = 1; insulin alone, n = 2; insulin + OADs, n = 4), and nine (37Á5%) were not using medication for diabetes. Five patients with diabetes (21%) started antidiabetes medication during the study (after first intake of study drug). †Safety population comprised all patients who received at least one dose of lanreotide autogel. One patient without diabetes was excluded from the ITT population (n = 89), owing to missing tumour volume assessment at baseline; one further patient was excluded from this analysis due to the absence of postbaseline IGF-1 measurements. ‡Hormonal control at LVA defined as GH ≤ 2Á5 lg/l and IGF-1 within age-and sex-matched normal ranges (hormonal data reported in the table are baseline measurements, not levels at LVA).
(continued) Lipid profiles, BMI and blood pressure during the study according to diabetic status
In the overall population, there was a statistically significant decrease in triglycerides, and a significant increase in HDL cholesterol (both considered improvements), and no significant changes in total cholesterol and LDL cholesterol ( Fig. 3; Figure S2 ). In patients with diabetes, there were no significant changes in any fasting lipids. In patients without diabetes, significant changes occurred in triglycerides (decrease) and HDL cholesterol (increase). All changes were small and likely to be of minor clinical relevance.
Body mass index did not significantly change from baseline to week 48 in the safety population overall [0Á0 kg/m 2 (95% CI: À0Á4; 0Á4), n = 61], with similar results in subgroups by diabetic status. There was a nonsignificant trend towards increased BP in patients with diabetes and decreased BP in patients without diabetes: change in SBP from baseline to week 48 with diabetes, 0Á9 mmHg (95% CI: À5Á4; 7Á2), n = 15; without diabetes, À4Á0 mmHg (95% CI: À8Á5; 0Á5), n = 48; change in DBP from baseline to week 48 with diabetes, 0Á9 mmHg (95% CI: À3Á1; 4Á8), n = 15; without diabetes, À2Á7 mmHg (95% CI: À6Á5; 1Á0), n = 48.
Glycaemic control, lipid profiles, BMI and blood pressure according to hormonal control at LVA
In the ITT population, normalized IGF-1 levels with GH levels ≤2Á5 lg/l (considered hormonal control) were observed in 27/62 Fig. 1 Glycaemic control during the study overall and according to diabetic status at baseline (safety population). Patients with diabetes fulfilled one or more of the following criteria at baseline: a medical history of diabetes (5/24 patients with diabetes did not have a recognized history of it); HbA 1c ≥6Á5%; FPG ≥7 mmol/l (≥126 mg/dl); previous/current use of antidiabetes medications (oral antidiabetic drug and/or insulin prescribed for diabetes). *Significant change from baseline (according to 95% CI). CI, confidence interval; FPG, fasting plasma glucose; HbA 1c , glycated haemoglobin.
(43Á5%) patients at week 48 and 30/88 (34Á1%) patients at LVA. 14 Among the 30 patients achieving hormonal control, six (20%) had diabetes (Table 1) . HbA 1c and FPG profiles during the study were similar in patients achieving and not achieving hormonal control at LVA, with no significant changes from baseline ( Fig. 4a and b) . Fasting lipids and changes in lipids (Fig. 3) in the overall population were similar for patients achieving and not achieving hormonal control at LVA (Fig. 4c) . Minor increases in HDL cholesterol occurred in patients with and without hormonal control at LVA, as well as minor decreases in triglycerides in patients without hormonal control at LVA; no other statistically significant changes occurred.
Changes in BMI in the ITT population according to hormonal control at LVA were similar to those in the safety population, with no significant changes in males or females with or without control. SBP changes were not significant in patients with control [À0Á9 mmHg (95% CI: À7Á3; 5Á6), n = 27] or without control [À4Á1 mmHg (95% CI: À8Á8; 0Á5), n = 35], with similar results observed for DBP [with control, À1Á5 mmHg (95% CI: À6Á2; 3Á1), n = 27; without control, À1Á8 mmHg (95% CI: À5Á9; 2Á4), n = 35].
Correlation analyses of IGF-1 and GH changes vs glucose and lipid changes
There were no correlations between IGF-1 or GH changes and changes in HbA 1c or FPG from baseline to week 48 (data not shown; ITT population). Similarly, there were no notable correlations between IGF-1 or GH changes and any lipid parameter. Statistical correlations did exist between IGF-1 changes and changes in total cholesterol and in LDL cholesterol, but were Fig. 2 Individual changes in glycaemic parameters from baseline to week 48, according to ADA threshold levels at baseline (safety population). ADA thresholds according to 2013 criteria for diabetes. The numbers of patients with changes in glycaemic levels that crossed ADA thresholds during the study (shift tables) are shown in Table 2 (overall population, patients with diabetes at baseline and patients without diabetes at baseline) and Table S2 (patients with/without diabetes at baseline). Glycaemic data for patients starting/changing antidiabetes medication after first intake of study drug are listed in Table S1 . ADA, American Diabetes Association; FPG, fasting plasma glucose; HbA 1c , glycated haemoglobin.
considered too weak to be clinically important (data not shown; ITT population).
Discussion
In treatment-na€ ıve patients with GH-secreting pituitary macroadenomas, 1-year treatment with the highest available lanreotide autogel dose (120 mg/4 weeks) had no overall adverse impact on mean glucose homoeostasis in the overall population, or in patients with or without diabetes. Some individual patients showed improvements in glycaemic parameters, including several who crossed below threshold levels for diabetes. These changes contributed to a significant mean reduction in HbA 1c in patients with diabetes. Nonetheless, mean changes in FPG were not significant. Furthermore, glycaemic control worsened in some patients, including nine who shifted to a worse composite glycaemic category by study end.
Mixed model analyses of the evolutions in HbA 1c and FPG during the study found significant interactions for both parameters between diabetic status at baseline and time point. Thus, adjusted mean decreases in HbA 1c and FPG over time were significantly greater in patients with diabetes vs those without. These findings support that glycaemic levels tended towards normalization in patients with diabetes during the study, while the Data are n (%) patients with data available at each time point in the safety population (i.e. excluding missing, n = 24/90 at week 24, and n = 30/90 at week 48 for overall population; n = 9/24 at week 24 and n = 10/24 at week 48 for patients with diabetes; n = 15/66 at week 24 and n = 20/66 at week 48 for patients without diabetes). Glucose control status defined as composite of HbA 1c and FPG levels (according to ADA criteria 13 for normal/mild/ diabetic HbA 1c and normal/mild/diabetic FPG) as follows: †(i) normal glycaemia (HbA 1c <5Á7% and FPG <5Á6 mmol/l); ‡(ii) mild hyperglycaemia (HbA 1c <6Á5% and FPG ≥5Á6 to <7Á0 mmol/l, or HbA 1c ≥5Á7 to <6Á5% and FPG <5Á6 mmol/l); §(iii) diabetic (HbA 1c ≥6Á5% or FPG ≥7Á0 mmol/l). Unshaded cells indicate no change in status relative to baseline; green cells indicate an improvement in status relative to baseline that crosses a glycaemic control threshold; red cells indicate deterioration. ADA, American Diabetes Association; FPG, fasting plasma glucose; HbA 1c , glycated haemoglobin. *Definition of patients with or without diabetes was based on whether or not they fulfilled one or more of the following criteria at baseline: a medical history of diabetes; HbA 1c ≥6Á5%; FPG ≥7 mmol/l (≥126 mg/dl); previous/current use of antidiabetes medications (oral antidiabetic drug or insulin prescribed for diabetes).
overall trend was to no change (although individual patients in both groups had levels that increased or decreased). It has been suggested that long-acting SSAs cause mild impairment of glucose tolerance, via reduced insulin secretion without concomitant increase in sensitivity. 9 However, the good glycaemic control observed in patients with diabetes in the PRIMARYS study is consistent with an observational study of 70 patients with acromegaly and diabetes, in which SSA treatment had a negative effect on insulin secretion without influencing glycaemic control. 16 With 92Á8% of the population receiving SSAs (31Á4% as first-line therapy), no difference was found between octreotide LAR and lanreotide autogel for HbA 1c , but the numbers of patients receiving each analogue were not reported. 16 The HbA 1c decrease in patients with diabetes in this study, which was both significant and clinically meaningful (albeit from a small number of patients), may be attributable at least in part to the maintenance of effective diabetes management and follow-up. Four patients started initial or further antidiabetes medication during the study, and participation in a trial may itself lead to increased adherence to therapy and/or lifestyle changestrials of diabetes medications have shown meaningful HbA 1c decreases with placebo. 17, 18 Improved glycaemic control may also be partly related to correction of GH excess, as GH antagonist treatment results in improved glycaemic parameters. 19 With respect to lanreotide, we did not find any clear correlation between changes in IGF-1 or GH and changes in glucose parameters. Lanreotide treatment had a modest positive impact on some lipid levels, both in the overall population and in patients without diabetes, and had no deleterious effects on lipid profiles. Broadly similar findings for glucose and lipids were observed in those with/without hormonal control during the study. These changes over 48 weeks were of minor clinical relevance, but are consistent with limited published information available on the effects of long-term SSA treatment of cardiovascular risk factors. 20 21 In contrast to our findings, the investigators found progressive glucose tolerance impairment with SSA treatment, independent of the degree of GH/IGF-I control. Evaluating cardiac risk factors in treatment-na€ ıve, first-line SSA-treated and first-line surgically cured patients with acromegaly (n = 13, 12 and 15, respectively) showed that after 1 year, each group had raised HbA 1c levels and increased left ventricular hypertrophy compared with matched controls. In contrast to surgically cured patients, however, SSA-treated patients also had increased prevalence of diabetes and increased Framingham Weibull risk score vs controls. 22 Among five somatostatin receptors, binding affinities for lanreotide are high for SSTR2 and SSTR5, and for octreotide are high for SSTR2 and moderate for SSTR3 and SSTR5. [23] [24] [25] [26] Our data add to the available evidence that treatment with lanreotide autogel 120 mg improves the signs and symptoms of acromegaly (as shown in the PRIMARYS study), 14 without compromising glycaemic control in most patients. These findings contrast with recent evidence for pasireotide LAR, which has high affinity for SSTR1, SSTR2, SSTR3 and SSTR5 (30-40-fold higher affinity for SSTR1 and SSTR5 than lanreotide and octreotide). 23, 24 In a phase-III trial (PAOLA study) of pasireotide LAR in patients with inadequately controlled acromegaly with either octreotide LAR 30 mg or lanreotide autogel 120 mg 13 , the most frequent adverse events (AEs) were hyperglycaemia (33% and 31% of patients receiving 40 mg and 60 mg pasireotide, respectively, vs 14% with active control) and diabetes (21% and 26% vs 8%). The active control group in this trial (n = 66) received continued treatment with either octreotide LAR 30 mg or lanreotide autogel 120 mg (treatment split not reported). 13 Furthermore, in a head-to-head comparison between pasireotide and octreotide LAR in 358 medically na€ ıve patients with acromegaly, more patients experienced hyperglycaemia-related AEs with pasireotide (57%) than octreotide (22%). 12 Therefore, although glycaemic disruption with SSAs that predominantly target SSTR2 cannot be ruled out for some individuals, it seems likely that AEs of this type are mediated via a pan-SSTR-binding profile such as that of pasireotide. Insulin sensitivity parameters were not investigated in the PRIMARYS study; as we have mentioned, reduced insulin secretion is a known effect of SSA treatment. 16, 27, 28 Our findings confirm, however, that any effect of lanreotide autogel 120 mg on insulin secretion does not hinder glycaemic control in most patients, irrespective of the presence of diabetes. The design of PRIMARYS as an open-label, uncontrolled study imposes a limitation on these findings. Furthermore, diabetic status was defined post hoc according to database records. The sample size for patients with diabetes was small (n = 24) and as low as 15 for some analyses of change from baseline. There was no control group, and statistical comparisons were limited by the post hoc and descriptive nature of the analyses, which were exploratory by nature and intended to be hypothesis generating. It would have been desirable to specifically monitor changes in diabetes management during the study and to investigate insulin sensitivity. Nevertheless, our analyses by hormonal control were consistent with those by diabetic status. Overall, the defined inclusion and exclusion criteria of PRI-MARYS allowed analysis of data from a homogeneous study population and provided useful information on the clinical effects of primary therapy with lanreotide autogel 120 mg, specifically in patients with GH-secreting macroadenomas.
In conclusion, although acromegaly itself can contribute to impaired glucose tolerance and diabetes onset, lanreotide autogel 120 mg every 4 weeks in the PRIMARYS study had no detrimental impact on glucose homoeostasis in the majority of patients, while, for a small proportion of individuals, it was associated with some worsening. In addition, a minor positive influence on lipid profiles was observed, suggesting that detrimental metabolic effects are not a major consideration when initiating long-term lanreotide treatment at the highest recommended dose in acromegaly. Fig. 4 Metabolic profiles during the study according to achievement of hormonal control at LVA (ITT population). A total of 30/88 patients (34%) with postbaseline IGF-1 measurement in ITT population achieved hormonal control (GH ≤ 2Á5 lg/l and IGF-1 within age-and sex-matched normal ranges) at LVA. *Significant change from baseline (according to 95% CI, there were no significant changes in glycaemic control parameters). CI, confidence interval; GH, growth hormone; HDL-C, high-density lipoprotein cholesterol; IGF-1, insulin-like growth factor-1; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; LVA, last postbaseline value available; TC, total cholesterol; TG, triglycerides.
